FI945586A0 - Selektiivinen solujen inaktivointi veressä - Google Patents

Selektiivinen solujen inaktivointi veressä

Info

Publication number
FI945586A0
FI945586A0 FI945586A FI945586A FI945586A0 FI 945586 A0 FI945586 A0 FI 945586A0 FI 945586 A FI945586 A FI 945586A FI 945586 A FI945586 A FI 945586A FI 945586 A0 FI945586 A0 FI 945586A0
Authority
FI
Finland
Prior art keywords
blood
selective cell
cell inactivation
elevated levels
subjects
Prior art date
Application number
FI945586A
Other languages
English (en)
Swedish (sv)
Other versions
FI945586A (fi
Inventor
Janice North
Original Assignee
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc filed Critical Quadra Logic Tech Inc
Publication of FI945586A0 publication Critical patent/FI945586A0/fi
Publication of FI945586A publication Critical patent/FI945586A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI945586A 1992-05-27 1994-11-28 Selektiivinen solujen inaktivointi veressä FI945586A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/889,707 US5776966A (en) 1992-05-27 1992-05-27 Selective cell inactivation in blood
PCT/CA1993/000215 WO1993024127A1 (en) 1992-05-27 1993-05-27 Selective cell inactivation in blood

Publications (2)

Publication Number Publication Date
FI945586A0 true FI945586A0 (fi) 1994-11-28
FI945586A FI945586A (fi) 1995-01-27

Family

ID=25395640

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945586A FI945586A (fi) 1992-05-27 1994-11-28 Selektiivinen solujen inaktivointi veressä

Country Status (23)

Country Link
US (1) US5776966A (fi)
EP (1) EP0642342B1 (fi)
JP (1) JP3174821B2 (fi)
KR (1) KR950701522A (fi)
AT (1) ATE194491T1 (fi)
AU (1) AU687734B2 (fi)
CA (1) CA2136447C (fi)
CZ (1) CZ283846B6 (fi)
DE (1) DE69329026T2 (fi)
DK (1) DK0642342T3 (fi)
ES (1) ES2147754T3 (fi)
FI (1) FI945586A (fi)
GR (1) GR3034529T3 (fi)
HU (1) HUT78021A (fi)
IL (1) IL105815A (fi)
MX (1) MX9303127A (fi)
NO (1) NO308506B1 (fi)
NZ (1) NZ252085A (fi)
PT (1) PT642342E (fi)
SK (1) SK143994A3 (fi)
TW (1) TW257674B (fi)
WO (1) WO1993024127A1 (fi)
ZA (1) ZA933723B (fi)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807881A (en) * 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
US5756541A (en) 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
CA2221912A1 (en) * 1997-11-21 1999-05-21 David Dolphin Photosensitizers with improved biodistribution and light-absorbing properties
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US6602274B1 (en) 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US6734192B1 (en) 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
WO2002064163A2 (en) 2001-02-15 2002-08-22 Qlt Inc. Reduction or prevention of pdt related inflammation
WO2002100326A2 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US20030103995A1 (en) * 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
DK1539929T3 (da) * 2002-06-28 2013-07-15 Life Technologies Corp Fremgangsmåder til genoprettelse af immunrepertoiret i patienter med immunologiske defekter i forbindelse med autoimmunitet og transplantation af organer eller hæmatopoeitiske stamceller
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
KR100604350B1 (ko) 2004-07-15 2006-07-25 학교법인 인제학원 광역학 치료용 광민감성 물질로 유용한 사이클릭테트라피롤 고분자와 이의 제조방법
ES2454974T3 (es) * 2007-06-27 2014-04-14 The General Hospital Corporation Aparato para la inhibición óptica de la terapia fotodinámica
US10328085B2 (en) 2014-05-09 2019-06-25 Uniwersytet Jagiellonski Cobalt porphyrins for the treatment of blood-related disorders
PL233504B1 (pl) 2014-05-09 2019-10-31 Univ Jagiellonski Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610241A (en) * 1984-07-03 1986-09-09 Gordon Robert T Atherosclerosis treatment method
US5011684A (en) 1985-09-05 1991-04-30 Beth Israel Hospital Association Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
DE3821254A1 (de) 1988-06-23 1990-01-04 Hoffmann Elektrokohle Schleifstueck fuer stromabnehmer sowie verfahren zu seiner herstellung
US5190966A (en) * 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US5028594A (en) * 1988-12-27 1991-07-02 Naxcor Use of photodynamic compositions for cytotoxic effects
US4960408A (en) * 1989-01-10 1990-10-02 Klainer Albert S Treatment methods and vaccines for stimulating an immunological response against retroviruses
US5149708A (en) * 1989-06-07 1992-09-22 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
US5214036A (en) * 1990-03-08 1993-05-25 University Of British Columbia Benzoporphyrin derivatives for photodynamic therapy

Also Published As

Publication number Publication date
IL105815A0 (en) 1993-09-22
CA2136447A1 (en) 1993-12-09
AU4057193A (en) 1993-12-30
NO308506B1 (no) 2000-09-25
US5776966A (en) 1998-07-07
TW257674B (fi) 1995-09-21
ATE194491T1 (de) 2000-07-15
CZ291894A3 (en) 1995-09-13
ES2147754T3 (es) 2000-10-01
KR950701522A (ko) 1995-04-28
DE69329026D1 (de) 2000-08-17
CA2136447C (en) 2001-06-19
PT642342E (pt) 2000-11-30
GR3034529T3 (en) 2000-12-29
CZ283846B6 (cs) 1998-06-17
JPH08501278A (ja) 1996-02-13
DK0642342T3 (da) 2000-10-09
ZA933723B (en) 1993-12-15
HU9403385D0 (en) 1995-02-28
NZ252085A (en) 1998-02-26
AU687734B2 (en) 1998-03-05
IL105815A (en) 2000-01-31
FI945586A (fi) 1995-01-27
WO1993024127A1 (en) 1993-12-09
DE69329026T2 (de) 2001-03-22
MX9303127A (es) 1994-06-30
NO944537L (no) 1995-01-20
NO944537D0 (no) 1994-11-25
EP0642342A1 (en) 1995-03-15
HUT78021A (hu) 1999-05-28
SK143994A3 (en) 1996-07-03
JP3174821B2 (ja) 2001-06-11
EP0642342B1 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
FI945586A0 (fi) Selektiivinen solujen inaktivointi veressä
PH23526A (en) Light array assembly for photoactivation patient treatment system
PH23617A (en) Pump block for interfacing irradiation chamber to photoactivation patient treatment system
IL126366A0 (en) Photopheresis treatment of leukocytes
DE59205846D1 (de) Azaheterocyclylmethyl-chromane als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems
DE3674941D1 (de) Ozonentkeimung von blut und blutprodukten.
DK0975214T3 (da) Forbedret opbevaring og opretholdelse af blodprodukter
DE68915834D1 (de) Herstellung von T-Zellen und T-Zellmembranen, verwendbar zur Verhütung und Behandlung von Autoimmunkrankheiten.
AU6950887A (en) Disposable temperature probe for photoactivation patient treatment system
ATE322162T1 (de) Photosensibilisator-enthaltende lagerungslösung zur inaktivierung von biologischen verunreinigungen
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
PH24585A (en) Irradiation chamber for photoactivation patient treatment system
EE03170B1 (et) Perifeerse vere mononukleaarsete rakkude tsütotoksilise aktiivsuse stimuleerimine IL-10 abil
ATE78164T1 (de) Verwendung von metalloporphyrin zur umkehr des toxischen effekts der tumortherapie.
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
RU97103883A (ru) Способ усиления эффективности действия противоопухолевого химиопрепарата
MD2259G2 (ro) Metodă de tratament al spondiloartralgiei autoimune la copii
ES8702863A1 (es) Procedimiento para la obtencion de un complejo salino de acido aspartico,magnesio y acido bromhidrico